| |
| |
|
| Insider
Information: |
Harper Sean E |
| Relationship: |
10% Owner |
| City: |
Thousand Oaks |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
9,846,811 |
|
|
Indirect Shares
|
735,984 |
|
|
| Direct
Value |
$57,490,483 |
|
|
|
Indirect Value
|
$9,221,880 |
|
|
| Total
Shares |
10,582,795 |
|
|
| Total
Value |
$66,712,363 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -71.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Amgen Inc |
AMGN |
EVP, Research & Develo... |
2018-07-16 |
56,082 |
|
0 |
Premium* |
|
|
Acelyrin, Inc. |
SLRN |
10% Owner |
2023-05-09 |
9,790,729 |
2023-05-09 |
0 |
Premium* |
|
|
Kyverna Therapeutics |
KYTX |
10% Owner |
2024-02-12 |
0 |
2024-02-12 |
735,984 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
64 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2014-04-27 |
4 |
D |
$111.41 |
$172,240 |
D/D |
(1,546) |
73,407 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2014-08-05 |
4 |
S |
$127.29 |
$1,782,126 |
D/D |
(14,000) |
59,503 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2014-12-31 |
4 |
D |
$160.63 |
$2,095,579 |
D/D |
(13,046) |
46,608 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2015-01-28 |
4 |
D |
$158.89 |
$153,011 |
D/D |
(963) |
45,645 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2015-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,940 |
49,585 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2015-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
54,577 |
104,162 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2015-03-27 |
4 |
D |
$160.55 |
$4,595,583 |
D/D |
(28,624) |
75,920 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2015-04-22 |
4 |
S |
$171.58 |
$4,804,240 |
D/D |
(28,000) |
47,920 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2015-04-25 |
4 |
D |
$167.91 |
$178,824 |
D/D |
(1,065) |
46,855 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2015-04-27 |
4 |
D |
$167.91 |
$264,458 |
D/D |
(1,575) |
45,280 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2016-01-28 |
4 |
D |
$150.47 |
$150,320 |
D/D |
(999) |
44,281 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2016-01-31 |
4 |
D |
$152.73 |
$99,427 |
D/D |
(651) |
43,894 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2016-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
45,268 |
89,162 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2016-03-25 |
4 |
D |
$149.24 |
$3,549,673 |
D/D |
(23,785) |
65,782 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2016-04-27 |
4 |
D |
$162.85 |
$270,168 |
D/D |
(1,659) |
64,123 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• – – |
2016-04-29 |
4 |
S |
$157.99 |
$3,456,134 |
D/D |
(21,875) |
42,248 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,477 |
46,725 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2017-01-28 |
4 |
D |
$157.16 |
$165,961 |
D/D |
(1,056) |
45,955 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2017-01-30 |
4 |
D |
$157.16 |
$80,623 |
D/D |
(513) |
45,442 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2017-01-31 |
4 |
D |
$154.43 |
$103,159 |
D/D |
(668) |
44,774 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2017-03-24 |
4 |
D |
$166.04 |
$2,013,733 |
D/D |
(12,128) |
55,945 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,551 |
60,496 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2017-10-09 |
4 |
AS |
$185.95 |
$283,574 |
D/D |
(1,525) |
59,156 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2017-11-13 |
4 |
AS |
$171.58 |
$261,660 |
D/D |
(1,525) |
57,631 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2017-12-12 |
4 |
AS |
$176.83 |
$269,666 |
D/D |
(1,525) |
56,106 |
0 |
- |
|
64 Records found
|
|
Page 2 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
